Adverse reactions of the new generation of tumor immunotherapy and its management strategy

doi:10.3760/cma.j.issn.1673-422X.2017.06.015

Abstract

Liu Zhongzheng, Xie Xiaodong. Adverse reactions of the new generation of tumor immunotherapy and its management strategy[J]. Journal of International Oncology, 2017, 44(6): 460-.

［1］ CouzinFrankel J. Breakthrough of the year 2013. Cancer immunotherapy［J］. Science, 2013, 342(6165): 1432-1433. DOI: 10.1126/science.342.6165.1432. ［2］张淑娟, 常建华. 肺癌的免疫治疗［J］. 国际肿瘤学杂志, 2015, 42(10): 776-779. DOI: 10.3760/cma.j.issn.1673422X.2015.10.016. ［3］ Ledford H. Melanoma drug wins US approval［J］. Nature, 2011, 471(7340): 561. DOI: 10.1038/471561a. ［4］ Poole RM. Pembrolizumab: first global approval［J］. Drugs, 2014, 74(16): 1973-1981. DOI: 10.1007/s4026501403145. ［5］ Kazandjian D, Suzman DL, Blumenthal G, et al. FDA approval summary: nivolumab for the treatment of metastatic nonsmall cell lung cancer with progression on or after platinumbased chemotherapy［J］. Oncologist, 2016, 21(5): 634-642. DOI: 10.1634/theoncologist.20150507. ［6］ Raedler LA. Opdivo (Nivolumab): second PD1 inhibitor receives FDA approval for unresectable or metastatic melanoma［J］. Am Health Drug Benefits, 2015, 8(Spec Feature): 180-183. ［7］ Markham A. Atezolizumab: first global approval［J］. Drugs, 2016, 76(12): 1227-1232. DOI: 10.1007/s4026501606188. ［8］ Markham A. Elotuzumab: first global approval［J］. Drugs, 2016, 76(3): 397-403. DOI: 10.1007/s4026501605400. ［9］ Weber J, Thompson JA, Hamid O, et al. A randomized, doubleblind, placebocontrolled, phase Ⅱ study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage Ⅲ or Ⅳ melanoma［J］. Clin Cancer Res, 2009, 15(17): 5591-5598. DOI: 10.1158/10780432.CCR091024. ［10］ Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma［J］. N Engl J Med, 2011, 364(26): 2517-2526. DOI: 10.1056/NEJMoa1104621. ［11］ Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as firstline treatment in stage ⅢB/Ⅳ nonsmallcell lung cancer: results from a randomized, doubleblind, multicenter phase Ⅱ study［J］. J Clin Oncol, 2012, 30(17): 2046-2054. DOI: 10.1200/JCO.2011.38.4032. ［12］ Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castrationresistant prostate cancer that had progressed after docetaxel chemotherapy (CA184043): a multicentre, randomised, doubleblind, phase 3 trial［J］. Lancet Oncol, 2014, 15(7): 700-712. DOI: 10.1016/S14702045(14)701895. ［13］ Lebbé C, Weber JS, Maio M, et al. Survival followup and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase Ⅱ studies［J］. Ann Oncol, 2014, 25(11): 2277-2284. DOI: 10.1093/annonc/mdu441. ［14］ Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigatorchoice chemotherapy for ipilimumabrefractory melanoma (KEYNOTE002): a randomised, controlled, phase 2 trial［J］. Lancet Oncol, 2015, 16(8): 908-918. DOI: 10.1016/S14702045(15)000832. ［15］ Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PDL1positive, advanced nonsmallcell lung cancer (KEYNOTE010): a randomised controlled trial［J］. Lancet, 2016, 387(10027): 1540-1550. DOI: 10.1016/S01406736(15)012817. ［16］ Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma［J］. N Engl J Med, 2015, 372(26): 2521-2532. DOI: 10.1056/NEJMoa1503093. ［17］ Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma［J］. JAMA, 2016, 315(15): 1600-1609. DOI: 10.1001/jama.2016.4059. ［18］ Weber JS, D′angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after antiCTLA4 treatment (CheckMate 037): a randomised, controlled, openlabel, phase 3 trial［J］. Lancet Oncol, 2015, 16(4): 375-384. DOI: 10.1016/S14702045(15)700768. ［19］ Rizvi NA, Mazières J,Planchard D, et al. Activity and safety of nivolumab, an antiPD1 immune checkpoint inhibitor, for patients with advanced, refractory squamous nonsmallcell lung cancer (CheckMate 063): a phase 2, singlearm trial［J］. Lancet Oncol, 2015, 16(3): 257-265. DOI: 10.1016/S14702045(15)700549. ［20］ Motzer RJ, Rini BI, Mcdermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase Ⅱ trial［J］. J Clin Oncol, 2015, 33(13): 1430-1437. DOI: 10.1200/JCO.2014.59.0703. ［21］ Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamouscell nonsmallcell lung cancer［J］. N Engl J Med, 2015, 373(2): 123-135. DOI: 10.1056/NEJMoa1504627. ［22］ Lacouture ME, Wolchok JD, Yosipovitch G, et al. Ipilimumab in patients with cancer and the management of dermatologic adverse events［J］. J Am Acad Dermatol, 2014, 71(1): 161-169. DOI: 10.1016/j.jaad.2014.02.035. ［23］ Klein O, Ebert LM, Nicholaou T, et al. MelanAspecific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with antiCTLA4［J］. Clin Cancer Res, 2009, 15(7): 2507-2513. DOI: 10.1158/10780432.CCR082424. ［24］ Cheng R, Cooper A, Kench J, et al. Ipilimumabinduced toxicities and the gastroenterologist［J］. J Gastroenterol Hepatol, 2015, 30(4): 657-666. DOI: 10.1111/jgh.12888. ［25］ Ryder M, Callahan M, Postow MA, et al. Endocrinerelated adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution［J］. Endocr Relat Cancer, 2014, 21(2): 371-381. DOI: 10.1530/ERC130499. ［26］ Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab associated hepatitis: imaging and clinicopathologicfindings［J］. Invest New Drugs, 2013, 31(4): 1071-1077. DOI: 10.1007/s1063701399396. ［27］ Marrone KA, Ying W, Naidoo J. Immunerelated adverse events from immune checkpoint inhibitors［J］. Clin Pharmacol Ther, 2016, 100(3): 242-251. DOI: 10.1002/cpt.394. ［28］ Choi JN. Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab［J］. Semin Cutan Med Surg, 2014, 33(1): 40-48. ［29］ Nancey S, Boschetti G, Cotte E, et al. Blockade of cytotoxic Tlymphocyte antigen4 by ipilimumab is associated with a profound longlasting depletion of Foxp3+ regulatory T cells: a mechanistic explanation for ipilimumabinduced severe enterocolitis?［J］. Inflamm Bowel Dis, 2012, 18(8): E1598-E1600. DOI: 10.1002/ibd.21927. ［30］ Tarhini A. Immunemediated adverse events associated with ipilimumab ctla4 blockade therapy: the underlying mechanisms and clinical management［J］. Scientifica(Cairo), 2013, 2013: 857519. DOI: 10.1155/2013/857519.

[1]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[2]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[5]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[6]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[7]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[8]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[9]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[10]	Guo Ciliang, Jiang Chunping, Wu Junhua. Gut microbiome and tumor immunotherapy [J]. Journal of International Oncology, 2023, 50(7): 432-436.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.
[13]	Gu Anqin, Long Jinhua, Jin Feng. Clinical research progress of immunotherapy for nasopharyngeal carcinoma [J]. Journal of International Oncology, 2023, 50(5): 299-303.
[14]	Ding Hao, Ying Jintao, Fu Maoyong. Research progress of CAR-T in the treatment of esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(4): 231-235.
[15]	Ma Pengcheng, Chen Yu. Research progress of primary pulmonary lymphoepithelioma-like carcinoma [J]. Journal of International Oncology, 2023, 50(3): 174-178.

Adverse reactions of the new generation of tumor immunotherapy and its management strategy

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments